Cell & Gene Exchange, May 2017: Sigilon, Inc

June 16, 2017
Sigilon is developing curative treatments for chronic diseases using new biomaterials that can shield implanted cells from immune attack. Treatments based on the Sigilon technology platform include cell implants that act as responsive “living pills,” providing more natural control for diseases currently treated with intermittent injection or infusion. These diseases include genetic disorders that require protein replacement as well as disorders that require dynamic protein delivery such as type 1 diabetes. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life. Sigilon technology originated from research conducted at the Massachusetts Institute of Technology and Harvard Medical School. Based in Cambridge, Massachusetts, Sigilon was founded with major support from Flagship Pioneering. Sigilon is also exploring partnering opportunities in order to maximize the impact of its groundbreaking technology. Speaker: Devyn Smith – COO and Head of Strategy
Previous Video
Cell & Gene Exchange, May 2017: Calimmune, Inc.
Cell & Gene Exchange, May 2017: Calimmune, Inc.

Calimmune is accelerating the promise of stem cell gene therapy to liberate patients from chronic and curre...

Next Video
Cell & Gene Exchange, May 2017: MEDIPOST America
Cell & Gene Exchange, May 2017: MEDIPOST America

MEDIPOST develops allogeneic stem cell products using multi-potent human Umbilical Cord Blood-derived Mesen...